Core Viewpoint - Harbin Fuerjia Technology Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, primarily due to optimization of offline channels and increased promotional expenses, while maintaining a strong brand presence in the professional skincare market [4][9]. Company Overview - Harbin Fuerjia Technology Co., Ltd. is listed on the Shenzhen Stock Exchange under the stock code 301371, focusing on the development, production, and sales of professional skincare products [2]. - The company has established a diverse product system, including medical devices and functional skincare products, to meet various market demands [3][9]. Financial Performance - For the reporting period, the company achieved operating revenue of 863.11 million yuan, a decrease of 8.15% compared to the same period last year [4]. - The net profit attributable to shareholders decreased by 32.54% to 229.66 million yuan, with a significant drop in cash flow from operating activities by 54.69% [4][9]. Business Operations - The company employs a multi-channel sales strategy, integrating online and offline channels, with significant sales through platforms like Tmall, Douyin, and JD [3][11]. - The sales model includes direct sales, distribution, and consignment, with direct sales accounting for 62.12% of total revenue [5][6]. Market Position and Strategy - The professional skincare product market is expected to grow, with the market size projected to reach 518.5 billion yuan by 2026, driven by increasing consumer demand for high-quality products [9]. - The company focuses on brand promotion and marketing strategies, leveraging both online and offline channels to enhance brand visibility and consumer engagement [7][11]. Research and Development - The company has established a robust R&D system, collaborating with third-party research institutions to innovate and improve product offerings [8][12]. - As of June 30, 2025, the company holds 31 approved patents and has several ongoing projects aimed at expanding its product line in the medical device sector [13][14]. Industry Trends - The skincare industry is witnessing a shift towards professional skincare products, with consumers increasingly prioritizing product efficacy and safety [9][10]. - The company is well-positioned to capitalize on these trends, focusing on innovative product development and strategic market positioning to maintain its competitive edge [10][12].

Core Viewpoint - After going public, the company's profitability has been continuously declining despite revenue growth [3][5]. Financial Performance - In 2024, the company achieved revenue of 2.017 billion yuan, a year-on-year increase of 4.32%, while net profit was 661 million yuan, a year-on-year decrease of 11.77%, marking two consecutive years of decline [5][9]. - The company reported a revenue of 1.934 billion yuan in 2023, with a year-on-year growth of 9.29%, but net profit fell by 11.56% to 749 million yuan [5][4]. - For Q1 2025, the company reported revenue of 301 million yuan, a year-on-year decrease of 26.39%, and net profit of 91.384 million yuan, down 39.77% [9][10]. Expense Analysis - In 2024, sales expenses reached 748 million yuan, a year-on-year increase of 40.53%, significantly outpacing revenue growth and accounting for approximately 37% of total revenue [5][6]. - The company's R&D expenses were 34.82 million yuan in 2024, growing by 6.04%, but this growth was much lower than that of sales expenses [5][6]. Production Capacity and Utilization - The company increased its cosmetic production capacity in 2024, but the utilization rate dropped significantly, with medical device capacity utilization at 79.18% and cosmetic capacity at 59.66% [5][6][8]. - The company had a medical device capacity of approximately 141.12 million standard units and cosmetic capacity of about 176.4 million standard units in 2024 [6][8]. Dividend Distribution - Since going public, the company has distributed a total of 1 billion yuan in cash dividends, with the controlling shareholder receiving approximately 840 million yuan [11].

入大、新旧产业融合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、 退市风险高等特点，投资者面临较大的市场风险。投资者应充分了解创业板的投 资风险及本公司所披露的风险因素，审慎作出投资决定。 哈尔滨敷尔佳科技股份有限公司 （哈尔滨市松北区美谷路 500 号） 首次公开发行股票并在创业板上市 招股说明书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 创业板投资者风险提示：本次发行股票拟在创业板上市，创业板公司具有创新投 哈尔滨敷尔佳科技股份有限公司 首次公开发行股票并在创业板上市招股说明书 声 明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1 哈尔滨敷尔佳科技股份有 ...

创业板投资者风险提示：本次发行股票拟在创业板上市，创业板公司具有创新投 入大、新旧产业融合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、 退市风险高等特点，投资者面临较大的市场风险。投资者应充分了解创业板的投 资风险及本公司所披露的风险因素，审慎作出投资决定。 哈尔滨敷尔佳科技股份有限公司 （哈尔滨市松北区美谷路 500 号） 首次公开发行股票并在创业板上市 招股意向书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 哈尔滨敷尔佳科技股份有限公司 首次公开发行股票并在创业板上市招股意向书 声 明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 哈尔滨敷尔佳科 ...

投入大、新旧产业融合存在不确定性、尚处于成长期、经营风险高、业绩不稳 定、退市风险高等特点，投资者面临较大的市场风险。投资者应充分了解创业 板的投资风险及本公司所披露的风险因素，审慎作出投资决定。 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 创业板投资者风险提示：本次发行股票拟在创业板上市，创业板公司具有创新 哈尔滨敷尔佳科技股份有限公司 首次公开发行股票并在创业板上市招股说明书（注册稿） 哈尔滨敷尔佳科技股份有限公司 （哈尔滨市松北区美谷路 500 号） 首次公开发行股票并在创业板上市 招股说明书 （注册稿） 声明：本公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。 本招股说明书（注册稿）不具有据以发行股票的法律效力，仅供预先披露之用。 投资者应当以正式公告的招股说明书作为投资决定的依据。 声 明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定 ...